1. Medtech Insight
  2. >>Archive

Immunexpress Looks To Leverage U.S. Anti-Infection Incentives With Unique Sepsis Diagnostic

The Seattle company's SeptiCyte system is designed to directly quantify molecular markers of sepsis from patient blood samples and tell doctors the probability that a patient has sepsis within four hours, allowing for aggressive treatment of sepsis or, if the test result is negative, preventing unnecessary antibiotics.

Seattle-based startup Immunexpress is set to complete an FDA de novo filing for its SeptiCyteLab sepsis test that it says tells the physician the probability the patient has sepsis within a few hours. That would be a big step up from current sepsis diagnostics that can take over a day to complete and often provide no useful information, the firm says.

The company hopes FDA will clear SeptiCyte Lab by the end of 2015 with a market launch set for the...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

More from Medtech Insight

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By Elizabeth Orr

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.